Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmunoTACE for hepatocellular carcinoma
ISRCTN11889464Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jan 2014
- Modality
- Small Molecules, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
01
Overview
Phase 2, open-label trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine and cyclophosphamide in hepatocellular carcinoma (HCC), sponsored by University of Birmingham. Started Jan 2014; status: completed.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccinecyclophosphamide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ISRCTN11889464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11889464.